Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.22
-0.29 (-2.76%)
At close: Jul 24, 2026, 4:00 PM EDT
10.25
+0.03 (0.29%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Telix Pharmaceuticals Employees
As of December 31, 2025, Telix Pharmaceuticals had 1,184 total employees, including 1,120 full-time and 64 part-time employees. The number of employees increased by 950 or 405.98% compared to the previous year.
Employees
1,184
Change
950
Growth
405.98%
Revenue / Employee
$678,880
Profits / Employee
-$6,018
Market Cap
3.48B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,184 | - | - | 1,120 | 64 |
| Mar 31, 2024 | 431 | 197 | 84.19% | 415 | 16 |
| Dec 31, 2022 | 234 | 76 | 48.10% | 234 | 0 |
| Dec 31, 2021 | 158 | - | - | 158 | 0 |
| Dec 31, 2017 | 9 | - | - | 9 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcus Biosciences | 601 |
| Denali Therapeutics | 507 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 263 |
| Structure Therapeutics | 233 |
| Alumis | 227 |
| IDEAYA Biosciences | 145 |
| Parabilis Medicines | 145 |
TLX News
- 3 days ago - TLX591-Tx ProstACT SELECT Study Published in Cancers Journal - GlobeNewsWire
- 3 days ago - Telix Pharma Q2 Revenue Rises 21%; Doses First Patient In Phase 3 LUTEON Trial; Shares Jump - Nasdaq
- 3 days ago - Telix Pharmaceuticals (TLX) Reports Strong Q2 Revenue Growth and Upbeat FY 2026 Outlook - GuruFocus
- 3 days ago - Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business - Nasdaq
- 4 days ago - Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewsWire
- 4 days ago - Telix Pharmaceuticals Earnings release: Q2 2026 - Filings
- 4 days ago - Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer - GlobeNewsWire
- 8 days ago - Telix Opens Australian GMP Facility; Doses First Patient In Phase 2 Prostate Cancer Trial - Nasdaq